New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
Altimmune presented new analyses from its IMPACT Phase 2b trial showing pemvidutide drives concurrent improvements in liver fat, inflammation, and fibrosis markers at 24 weeks. AI-based digital pathology using qFibrosis confirmed significant antifibrotic effects, with 68.6% of patients on the 1.2 mg dose achieving at least one stage of fibrosis regression versus 29.6% on placebo.
Key figures
- Drug Name
- pemvidutide
- Phase Of Trial
- Phase 2b
- Enrollment count
- 212
- Trial duration weeks
- 48
- Analysis timepoint weeks
- 24
- Fibrosis regression 1.2mg
- 68.6%
- Fibrosis regression 1.8mg
- 54.5%
- Fibrosis regression placebo
- 29.6%
- Concurrent improvement 1.2mg
- 37.8%
- Concurrent improvement 1.8mg
- 22.7%
- Concurrent improvement placebo
- 8.3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.